FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington

- D.C. 20540	
n, D.C. 20549	OMB APPROVAL
	OIVID APPROVAL

OMB Number:	3235-0287				
Estimated average burd	len				
hours per response.	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Sethuraman Natarajan</u>					2. Issuer Name and Ticker or Trading Symbol Entrada Therapeutics, Inc. [TRDA]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify			
(Last) (First) (Middle) C/O ENTRADA THERAPEUTICS, INC. 6 TIDE STREET				10	3. Date of Earliest Transaction (Month/Day/Year) 10/28/2021						X Officer (give title Other (specify below) Chief Scientific Officer				
(Street) BOSTON			02210 (Zip)	4.	If Ame	endment, [Oate o	f Original File	ed (Month/D	ay/Year)	Line) <mark>K</mark> Form fil	led by One F led by More	iling (Check Ap Reporting Perso than One Repo	n
(City)			ble I - Non-De	erivati	ve Se	curities	s Ac	quired, D	isposed (of, or Be	neficially	/ Owned			
1. Title of Security (Instr. 3) 2. Trans: Date (Month/L			е	Execution Date,		Code (Instr.		ed (A) or str. 3, 4 and !	5. Amount of Securities Beneficially Owned Follor Reported		5. Ownership Form: Direct [D) or Indirect [I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code V	Amount	(A) o	r Price	Transacti (Instr. 3 a	on(s)		(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	n Date Ex e (Month/Day/Year) if a	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	11(3)	
Stock Option (Right to Buy)	\$20	10/28/2021		A		243,639		(1)	10/28/2031	Common stock	243,639	\$0	243,639	D	

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the "Vesting Start Date"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date.

/s/ Jared Cohen, as Attorney-in-

Fact

11/01/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.